These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11832981)

  • 1. Rofecoxib-associated upper gastrointestinal bleed: a case report.
    Freedman GM; Kreitzer JM; Badola R
    Mt Sinai J Med; 2002; 69(1-2):105-6. PubMed ID: 11832981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of the VIGOR study. Rofecoxib halves the complication rate].
    MMW Fortschr Med; 2001 Jun; 143(23):35. PubMed ID: 11460417
    [No Abstract]   [Full Text] [Related]  

  • 3. Upper gastrointestinal toxicity of rofecoxib and naproxen.
    Delgado Fernández M; Zambrana García JL; Diez García F
    N Engl J Med; 2001 May; 344(18):1398; author reply 1398-9. PubMed ID: 11336056
    [No Abstract]   [Full Text] [Related]  

  • 4. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
    Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
    Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
    Choi HK; Seeger JD; Kuntz KM
    Am J Med; 2004 May; 116(9):621-9. PubMed ID: 15093759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine].
    MMW Fortschr Med; 2004 Mar; 146(13):61. PubMed ID: 15219139
    [No Abstract]   [Full Text] [Related]  

  • 8. [A critical evaluation of side effect data on COX-2 inhibitors].
    Pomp E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):476-80. PubMed ID: 11961974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of misoprostol in upper gastro-intestinal lesions in arthritic patients on non-steroidal anti-inflammatory drugs (NSAIDS)--an Indian experience.
    Bhatt CB; Pipalia DH; Naik SR; Tilve GH
    J Postgrad Med; 1988 Oct; 34(4):224-8. PubMed ID: 3151214
    [No Abstract]   [Full Text] [Related]  

  • 10. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
    Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracranial hypertension induced by rofecoxib.
    Jacob S; Rajabally YA
    Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
    MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
    [No Abstract]   [Full Text] [Related]  

  • 13. [The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
    Kellner H
    Z Gastroenterol; 2001 May; 39(5):443-5. PubMed ID: 11413920
    [No Abstract]   [Full Text] [Related]  

  • 14. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
    Wolfe F; Zhao S; Pettitt D
    J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
    McCarthy DM
    Eur J Surg Suppl; 2002; (587):89-99. PubMed ID: 16144207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
    Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Keeping patients with arthritis out of the hospital.
    Spiegel M
    Manag Care Interface; 1998 Jun; 11(6):81-5. PubMed ID: 10181565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial.
    Biancone L; Tosti C; Geremia A; Fina D; Petruzziello C; Emerenziani S; Pallone F
    Aliment Pharmacol Ther; 2004 Apr; 19(7):755-64. PubMed ID: 15043516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gastrointestinal complications under NSAID treatment in the doctor's office].
    Hollenz M; Labenz J
    MMW Fortschr Med; 2004 Dec; 146(49):42, 44. PubMed ID: 15646716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.